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1. ABSTRACT: 
The role of the carboxy terminal tail of the chicken gonadotropin-releasing hormone 
receptor was determined by testing the activity of a series of chicken gonadotropin-
releasing hormone receptors with progressive deletions in their carboxyl terminus. 
The 55 amino acid carboxy terminal tail of the chicken gonadotropin-releasing 
hormone receptor was progressively truncated, resulting in cS320STOP, cR330STOP, 
cS337STOP, cS346STOP, cT35ISTOP, cD356STOP, cS366STOP and cC375STOP 
truncated mutants, which were all tested in parallel with the wild type chicken 
gonadotropin-releasing hormone receptor. 
Truncation of the entire carboxy terminal tail from the chicken gonadotropin-releasing 
hormone receptor, cS320STOP abolished gonadotropin-releasing hormone binding 
and gonadotropin-releasing hormone-induced inositol phosphate production. The loss 
of gonadotropin-releasing hormone binding by the cS320STOP-truncated mutant 
suggests that this receptor is possibly not expressed on the cell membrane, which 
might be due to improper receptor folding by cS320STOP. The carboxy terminal tail 
of the chicken gonadotropin-releasing hormone receptor might therefore be required 
for proper folding of newly formed chicken gonadotropin-releasing hormone 
receptors and expression of these receptors on the cell membrane. The cR330STOP 
mutant had a maximal gonadotropin-releasing hormone binding of-12%, which is the 
lowest receptor expression detected. The amino acid region between P319 and L329 
might therefore play a role in receptor expression. Progressive increase in the carboxy 
terminal tail from L329 resulted in progressive increase in the receptor expression. 
Maximal gonadotropin-releasing hormone binding levels reached wild type levels at 
truncation of the cGnRHR at S366 . These results indicate that the first 45 amino 
region, ie. between P319 and S366 of the chicken gonadotropin-releasing hormone 
receptor carboxy terminal tail contains elements that promote receptor expression. 
Gonadotropin-releasing hormone-induced inositol phosphate production was 
enhanced for all the truncated receptors except cR330STOP and cS337STOP, though 
all the truncated receptors had coupling efficiency values larger than the wild type 
chicken gonadotropin-releasing hormone receptor. This enhanced inositol phosphate 
production might be due to an increased coupling efficiency between the truncated 
chicken gonadotropin-releasing hormone receptors and the aq111 -type G-protein. 
However, none of the truncated chicken gonadotropin-releasing hormone receptors 
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have left-shifted EC50 values, indicating that coupling efficiency did not increase. 
Alternatively, a loss or retardation in receptor desensitization and/ or internalization 
for the truncated chicken gonadotropin-releasing hormone receptor mutants might be 
responsible for the enhanced gonadotropin-releasing hormone-induced inositol 
phosphate production by the truncated chicken gonadotropin-releasing hormone 
receptors. 
The chicken gonadotropin-releasing hormone receptor has a highly conserved 
cysteine residue in position 328 that might be palmitoylated. Replacing this cysteine 
in the chicken gonadotropin-releasing hormone receptor with an alanine [cC328A] 
increased receptor expression 2 fold, reduced maximal inositol phosphate production 
to -69% and severely impaired coupling efficiency to 30% relative to the wild type 
levels. This finding indicates that C328 might be palmitoylated and is required for 
receptor coupling. 
In conclusion, the ammo terminal region of the chicken gonadotropin-releasing 
hormone receptor carboxy terminal tail increases receptor expression, either by 
affecting the transport of newly synthesized chicken gonadotropin-releasing hormone 
receptors to the plasma membrane and/or the proper folding of this receptor. The 
intracellular carboxy terminal tail of the chicken gonadotropin-releasing hormone 
receptor might play a negative role in G-protein coupling. However, the enhanced 
inositol phosphate production from the truncated chicken gonadotropin-releasing 
hormone receptors could be due to reduced internalization and/ or desensitization of 
the carboxy terminal truncated receptors. Point-mutation of C
328 to A resulted in 
decreased coupling suggesting that C328 may be a palmitoylation site and might play a 
role in coupling or desensitization. 
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2. INTRODUCTION 
2.1 GENERAL INTRODUCTION 
The gonadotropin-releasing hormone [GnRH] 1s a decapeptide, synthesised by 
enzymatic cleavage of a large precursor protein in neurons of the medial basal 
hypothalamus. It plays a major role in maintaining homeostasis of the neuro-
endocrine reproductive axis. This hormone product is secreted via the hypophyseal 
blood circulation in a pulsatile manner to the anterior pituitary, where it binds with 
high affinity to the GnRH receptors [GnRHRs] expressed on the plasma membrane of 
gonadotropes. Upon binding of GnRH they mediate the synthesis and release of the 
gonadotropins, luteinizing hormone [LH] and follicle-stimulating hormone [FSH] 
which regulate gonadal steroidogenesis and gametogenesis. Early studies on 
regulation of LH release from gonadotropes showed that the pulse timing as well as 
the concentration of GnRH is critical for gonadotropin release (Lui and Jackson, 
1984). Chronic doses of GnRH administration to gonadotropes, was found to have an 
inhibitory effect on gonadotropin secretion from gonadotropes in a number of 
different species, such as in sheep (McIntosh and McIntosh, 1985), chicken (King et 
al., 1986) and rat (Hawes and Conn, 1992). This phenomenon was later exploited 
clinically in the treatment of pathophysiological disorders linked to the reproductive 
system, for example precocious puberty (Boepple et al., 1986), breast cancer (Manni 
et al., 1986), and prostate cancer (Labrie et al., 1986). This revolutionised the research 
field in reproductive physiology and triggered the design and synthesis of many novel 
GnRH agonists and antagonists. 
The primary amino acid sequence of mammalian GnRH was identified by Matsuo et 
al. ( 1971) who isolated this peptide from pig hypothalamus. Since then different 
forms of GnRH has been identified from both mammalian and non-mammalian 
species as seen in figure 2.1 (King and Millar, 1995; Sealfon et al., 1997). Most 
species have more than one form of GnRH. Mammalian GnRH controls the 
reproductive axis in mammals, while in chickens it is CI GnRH. The N- and C-
terminal domains of GnRHs are highly conserved and are both required for binding to 
the GnRHR. The N-terminal domain is however more important for GnRHR 
activation (Sealfon et al., 1997). GnRH is believed to take on a constrained form 
when it is in the active conformation. A glycine residue is conserved in position 6 of 
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believed to allow flexibility to the peptide during conformational transition between 
the active and inactive state (Sealfon et al., 1997). 
Mammal EHWS Y G LR PG 
Chicken I EHWS Y G LQ PG 
Seabream EHWS Y G LS PG 
Catfish EHWS H G LN PG 
Salmon EHWS Y G WL PG 
Dogfish EHWS H G WL PG 
Chicken II EHWS H G WY PG 
Lamprey m EHWS HDWK PG 
Lamprey I EH Y S LE WK PG 
Tunicate I EHWS DY FK PG 
Tunicate II EHWS L CHA PG 
Figure 2.1 Primary amino acid sequence of GnRH from mammalian and non-mammalian species. 
Highly conserved residues are indicated in red 
2.2 GnRHR SIGNALING 
All G-protein coupled receptors [GPCRs] transduce signals via heterotrimeric GTP-
binding proteins [G-proteins] that consist of a a , P- and y-subunit. In the inactive state 
the a-subunit binds GDP and is associated with PY, while in the active state the a-
subunit is bound to GTP and is dissociated from the Py-subunit. A number of G-
proteins, including Gas, Ga0 , Gai, Gaq, etc. have been identified by combining 
molecular cloning techniques with the inhibitory and stimulatory effects of bacterial 
toxins on specific G-protein classes (Neer, 1995). Early studies on gonadotrope 
stimulation with GnRH showed that activation of the GnRHR leads to an increased 
release in inositol phosphates [IPs] and calcium [Ca2+] mobilization, which can occur 
in the presence of pertussis toxin [PTX] (Naor et al., 1986). Stimulation of mouse 
gonadotrope [aT3-1] cell membranes in the presence of an antibody against PTX-
insensitive Gaq111 resulted in a marked decrease in IP production, suggesting that the 
GnRHR couples to Gaq111 (Hsieh and Martin, 1992). Ligand stimulation of the 
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GnRHR couples to Gaq111 (Hsieh and Martin, 1992). Ligand stimulation of the 
GnRHR induces a conformational change in the receptor. The activated GnRHR in 
turn catalyses Gaq;11 to exchange GDP for GTP, resulting in G-protein activation. The 
activated GTP-bound Gaq;11 dissociates from the PY subunits and relays the message 
to P-inositide specific phospholipase C [PLC-Pl PLC-P in turn hydrolyses the 
membrane embedded phosphatidylinositol 4,5-bisphosphate [PIP2] into second 
messengers inositol 1,4,5-trisphosphate [IP3] and diacylglycerol [DAG]. The 
generated IP3 and DAG promote the mobilization of Ca2+ from the endoplasmic 
reticulum [ER] stores and activates protein kinase C [PKC] respectively. This results 
in the propagation of a signaling cascade that culminates in the synthesis and 
exocytosis of LH and FSH from gonadotropes (Stojilkovic et al., 1994). 
Various GPCRs have been shown to mediate signals via more than one G-protein, for 
example the thyroid-stimulating hormone receptor [TSHR] (Allgeier et al., 1994) and 
a 2A-adrenergic receptor [ a2A-AR] ( Chabre et al., l 994 ). Such promiscuity allows the 
activation of more than one signaling system by a single receptor type. Arora et al. 
(1998) and Ulloa-Aguirre et al. (1998) respectively, demonstrated that GnRH-induced 
activation of the mouse GnRHR [mGnRHR] and rat GnRHR [rGnRHR] results in 
increased cAMP production. Thus, in addition to transmitting signals via Gaq111 , the 
GnRHR also couples to Gas. Furthermore, Stanislaus et al. (1998) suggests that the 
GnRHR might also couple to Gai10. GnRH-induced signaling via Gaq;11 and Gas is, 
however, not only observed in mammalian GnRHRs, but also non-mammalian 
GnRHRs such as the catfish GnRHR [dGnRHR] (Tensen et al., 1997). 
GnRHR activation results in stimulation of the mitogen-activated protein kinase 
[MAPK] and Jun N-terminal kinase [JNK] pathways via PKC (Sundaresan et al., 
1996; Nurel et al., 1998). The MAPK and JNK signaling cascade each consist of 
serine/threonine kinases that phosphorylate transcription factors, resulting in 
trancriptional regulation of a variety of genes. Little is known about the role of the 
MAPK and JNK cascade in response to GnRH. However, there is evidence that these 
pathways activate transcription factors that are responsible for GnRH-regulated 
transcription of gonadotropins and the GnRHR (Roberson et al., l 99 5; Saunders et 
al., 1998; Nurel et al., 1998). The initial transcriptional regulation in response to 
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GnRH induction is presumably governed mainly by the GnRH-MAPK pathway, 
followed by the GnRH-JNK pathway (Nurel et al., 1998). 
2.3 CLONING OF THE GnRH RECEPTOR 
Research concerning the effects of GnRH on gonadotropes as well as identifying the 
molecular mechanism involved in this signaling event remained the focal point of 
reproductive research after the primary amino acid sequence of mammalian GnRH 
was elucidated (Matsuo et al., 1971). However, research in this field reached a turning 
point when the cDNA of the mGnRHR was cloned. RNA extracted from aT3-1 cells 
was used to express a functional GnRHR in Xenopus oocytes, which led to the 
construction of cDNA library of aT3-1 cells. These cDNA libraries were used to 
generate full-length cDNA clones of the mGnRHR by means of PCR, using 
degenerate oligonucleotides homologous to conserved transmembrane [TM] motifs of 
G-protein coupled receptors [GPCRs] (Tsutsumi et al., 1992). Shortly thereafter, 
GnRHRs were cloned from other mammalian species, for example rat (Eidne et al., 
1992), human (Chi et al., 1993), and sheep (Illing et al, 1993; Brooks et al., 1993). 
Alignment of their primary sequences revealed that these receptors share more than 
85% amino acid homology (Davidson et al., 1994). Hydrophobicity analysis showed 
that the GnRHR has seven putative TMs that are characteristic of GPCRs. These TMs 
are connected on the outside of the cell by three extracellular loops [ECLs] and on the 
inside by three intracellular loops [ICLs]. The most striking difference between the 
mammalian GnRHRs and other GPCRs is the absence of an intracellular C-terminal 
tail from mammalian GnRHRs, which is normally present in all GPCRs cloned 
[figure 2.2]. Recently, various non-mammalian GnRHRs were cloned, for example 
catfish (Tensen et al., 1997), frog (Troskie B., unpublished), goldfish (Illing et al., 
1999) and chicken (Sun Y., unpublished), which revealed significant differences to 
their mammalian counterparts. One of the most notable differences is that the 
intracellular C-terminal tail is present in all non-mammalian GnRHRs cloned [figure 
2.3]. The cloning of the GnRHR cDNAs from different species proves to be an 
invaluable tool, facilitating a closer look at the GnRHR in terms of its structure and 
the identification of domains important in ligand binding and G-protein coupling. 
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Figure 2.2 Diagram of the human GnRHR that lacks an intracellular C-tenninal tail, an N-linked 
glycosylation site [blue] and two disulphide bonds [red] are indicated. 
Figure 2.3. Diagram of the chicken GnRHR that possesses two conserved cysteine residues, one in 
TM3 and another in ECL2 that might possibly form a disulphide bond (red]. 
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2.4 G-PROTEIN COUPLING OF THE GnRHR 
The intracellular loop [ICL] domains are the only structural entities of the GPCRs 
protruding the intracellular milieu and therefore it is not surprising that these domains 
were shown to interact with the cytosolic G-proteins. Cooperativity between two or 
more ICL domains, including the C-terminal tail has been demonstrated to orchestrate 
receptor/G-protein coupling in various GPCRs, such as the M3-R (Blin et al., 1995), 
~2-AR (O'Dowd et al., 1988), AT1A-R (Hunyudy et al., 1994) and V2-R (Erlenbach 
and Wess, 1998). 
Arora et al. (1998) demonstrated that the first ICL of the mGnRHR possesses specific 
residues at the N- and C-terminus that are critical for Gas activation, but not Gaq1ll. 
Replacing the N-terminal L58 and C-terminal L73 ofICL I with A and R respectively 
dramatically reduced GnRH-induced cAMP response by 80%. Furthermore, 
substitution of the C-terminal S74 and L80 with E and A respectively, completely 
abolished GnRHR-mediated cAMP production. These point mutations did not 
interfere with GnRH-induced IP signaling. 
A highly conserved motif, DRYXXV/IXXPL [where Xis any amino acid] at the N-
terminus of ICL 2 in most GPCRs, is also present in the mammalian GnRHR at a 
homologous position with the exception of a serine residue replacing the putative 
tyrosine. Arora et al. (1995) reported that this specific serine residue is not involved in 
GnRHR/Gaq111 coupling. In contrast, mutation of D
138 to Nor E and substitution of 
R139 with Q significantly impaired GnRHR-mediated IP production. This suggests that 
these highly conserved residues play an important role in GnRHR/Gaq111 coupling or 
GnRHR activation (Arora et al., 1997; Ballesteros et al., 1998). 
Substituting L147 of the mGnRHR in the D138RSXXIXXPL147 motif with A or D, 
significantly reduced GnRH-induced IP production by more than 50 and 70% 
respectively. L147 is therefore involved in Gaq111 coupling of the GnRHR (Arora et al., 
1995). Interestingly, this hydrophobic residue is conserved in both mammalian and 
non-mammalian GnRHRs, except the chicken GnRHR [cGnRHR] that contains a 
larger hydrophobic phenylalanine instead of a leucine. A hydrophobic residue at this 
position might have a conserved role in coupling of the GnRHRs with Gaq111 (Moro et 
al., 1993). 
P146 of the human GnRHR [hGnRHR] is highly conserved in ICL 2 of both 
mammalian and non-mammalian GnRHRs. Coupling efficiency of the hGnRHR was 
8 
significantly reduced by substituting R145 with P, introducing a P-P motif (Sealfon et 
al., 1997). These results suggest that P146 of the GnRHR may be responsible for 
orientating ICL 2, presenting specific G-protein coupling domains of this loop to the 
G-protein and/or other loop domains that it may co-operate with during G-protein 
coupling. 
Ulloa-Aguirre et al. (1998) transiently expressed the third ICL of the rGnRHR into 
pituitary-derived lactotrope [GH3] cells stably transfected with the rGnRHR [GGH31
1 
cells]. This homologous co-expression inhibited Buserelin-induced IP response by 
20% as well as cAMP production by 30%. Thus, the third ICL of the rGnRH receptor 
may be involved in Gaq111 and Gas coupling in GGH31
1 cells. Myburg et al. (1998) 
demonstrated that substitution of A261 in the hGnRHR with bulky amino acids, such 
as F, E, K, L, and I abolished ligand-induced IP response. This data suggest that A261 , 
which is localized in the C-terminal domain of the hGnRHR ICL 3, plays a critical 
role in the coupling of this receptor to Gaq111. Some of the residues required for 
coupling are likely to interact directly with the G-protein, while others appear to be 
important for the conformational change within the receptor induced by ligand 
binding. 
2.5 THE ROLE OF THE INTRACELLULAR C-TERMINAL 
TAIL IN: 
• EXPRESSION 
Very little is known about the process in which newly synthesized GPCRs are folded 
and transported to the plasma membrane and which regions of these receptors are 
involved in receptor expression. Results from truncation and deletion mutations of the 
intracellular C-terminal tail from a number of different GPCRs suggest that this 
region contains certain amino acid residues that are involved in receptor expression. 
Partial truncation of the luteinizing hormone receptor [LHR] by 48 amino acids 
resulted in a marked reduction in receptor expression, which was less than half the 
level of the full-length LHR (Sanchez-Yagiie et al., 1992). A similar effect was 
observed in other GPCRs, including the RhR (Weiss et al., 1994) and parathyroid 
hormone receptor (Huang et al., 1995). In contrast, truncation of 60 and 70 amino 
acids from the NK2-R intracellular C-terminal tail resulted in a 3 .3 and 1.4 fold 
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increased receptor expression respectively (Alblas et al., 1995). This suggests that the 
LHR may possess positive regulatory elements in its C-terminal tail, as opposed to 
possible negative regulatory elements present in the C-terminal tail of the type 2 
neurokinin receptor [NKrR] that play a role in receptor expression. 
In a recent study, the addition of the cfGnRHR intracellular C-terminal tail to the 
rGnRHR resulted in a -5 fold higher receptor expression of the chimera compared to 
the wt rGnRHR (Lin et al., 1998). Similarly, when the intracellular C-terminal tail of 
the rTRHR was added to the rGnRHR, the chimeric rGnRHR/rTRHR-C-tail 
expression was increased 3. 1 fold in comparison to that of the wt rGnRHR (Heding et 
al., 1998). 
Sadeghi, et al. (1997) showed that the naturally occurring C-terminal tail truncated 
mutant V2R-R337stop [9 amino acid C-terminal tail length], present in patients 
suffering from X-linked recessive nephrogenic diabetes insipidus, is not expressed on 
the plasma membrane of African green monkey kidney [COS.M6] cells or HEK293 
cells. However, they found that the V2R-R337stop mutant is produced in similar 
quantities as the wt V 2R, but is only present in the immature Endoglycosidase H 
sensitive form. An additional length of 4 amino acids is required [V 2R-34 l stop] to 
yield a mature receptor form expressed on the cell surface that binds ligand and 
mediates arginine vasopressin stimulation. With the use of fluorescence microscopy 
Oksche et al. (1998) demonstrated that the V2R-R337stop mutant receptor is retained 
in the endoplasmic reticulum [ER], possibly due to improper folding of the truncated 
receptor. This may implicate the membrane proximal region of the C-terminal tail in 
proper folding of the wt V2R. Furthermore, Rozell et al. (1998) showed that immature 
forms of G-protein coupled LHR and follicle stimulating hormone receptor [FSHR] 
associate with the protein folding chaperone calnexin, which facilitates protein folding 
and prevents the migration of improperly folded proteins from the ER. Thus the 
improperly folded V2R-R337stop mutant receptor may possibly be retained in the ER 
by protein folding chaperones. Oksche et al. (1998) suggested that the distal region of 
the C-terminal tail is required for efficient expression of the V 2R. 
Using an in vitro retinal cell-free system, Deretic et al. (1996) demonstrated that 
addition of a monoclonal antibody directed against the C-terminal tail of the Rh-R 
significantly inhibited post-Golgi vesicle formation. This indicates that the C-terminal 
tail of the Rh-R may interact with proteins or factors involved in mediating post-Golgi 
vesicle formation, thus playing a role in protein sorting. 
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All these findings suggest that the intracellular C-terminal tail of GPCRs may be 
involved in the proper folding of the receptor and or transport of the receptor to the 
plasma membrane in which the C-terminal tail of the cGnRHR may play a role. The 
mammalian GnRHRs lack an intracellular C-terminal tail, yet they are expressed on 
the plasma membrane and are functional. In contrast the non-mammalian GnRHRs, 
like most GPCRs have an intracellular C-terminal tail. It would therefore be 
interesting to examine the role of the C-terminal tail of the cGnRHR in the receptor 
expression and activity. 
• COUPLING 
The intracellular C-terminal tail of several GPCRs has been shown to be important in 
G-protein coupling. For example the intracellular C-terminus of the type lB a-
adrenergic receptor [arn-AR] dramatically inhibited ligand-induced IP stimulation 
from the full-length arn-AR during homologous co-expression in human embryonic 
kidney [HEK-293] cells (Hawes et al., 1994). The importance of the C-terminal tail in 
coupling was also demonstrated with the rhodopsin receptor [Rh-R] (Weiss et al., 
1994), follicle-stimulating hormone receptor [FSHR] (Grasso et al, 1995), interleukin-
s receptor (Ben-Baruch et al., 1998), and calcitonin receptor (Findlay et al., 1994). 
In a gain-of-function study the intracellular C-terminal tail of the IP-linked type la 
vasopressin receptor [V1a-R] was replaced with that of the cAMP-linked type 2-
vasopressin receptor [V2-R]. The resultant vasopressin type 2 and la chimeric 
receptor gained a 28% Gas coupling ability, while reducing the maximal IP 
production by -20% (Erlenbach and Wess, 1998). Hence, the intracellular C-terminal 
tail appears to be involved in receptor/G-protein coupling of both IP- and cAMP-
linked GPCRs. 
Amongst other regions in the human P2-AR, the N-terminal portion of its intracellular 
C-terminal tail shares a high homology with other GPCRs. These include the P-AR 
subtype 1 and 2 from different species, the human muscarinic acetylcholine receptor 
subtype 1, 2, 3 and 4; as well as the human Rh-R. Therefore specific residues in the 
N-terminal region of the human P2-AR C-terminal tail were substituted and deleted to 
establish if the N-terminal portion is important in G-protein coupling. This resulted in 
decreased maximal adenylyl cyclase activation suggesting that the N-terminal region 
of the C-terminal tail plays a role in P2-AR coupling to Gs (O'Dowd et al., 1988). A 
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similar experiment was performed in the a 1-AR which activates the phospholipase C 
second messenger system. Thirteen amino acids in the N-terminal region of the a1-
AR intracellular C-terminal tail were replaced with that of the ~2-AR. The resultant 
chimera produced a decreased maximal IP activity without any change in receptor 
expression or binding affinity (Cotecchia et al., 1990). Thus, the N-terminal domain 
of the C-terminal tail appears to be important in receptor/G-protein coupling of 
c.Afv1P- and IP-linked GPCRs. 
The N-terminal domain of the C-terminal tail of a number of GPCRs possess one or 
more conserved cysteine residue that is palmitoylated for example in the type A and B 
endothelin receptors (Horstmeyer et al., 1996; Okamoto et al., 1997). Palmitoylation 
of the C-terminal tail of GPCRs is believed to form a fourth loop by anchoring the C-
terminal tail into the membrane. Alanine replacement of a cluster of five cysteine 
residues in the membrane proximal domain of the type A endothelin receptor [ETA-R] 
C-terminal tail abolished palmitoylation. The Gas coupling of this unpalmitoylated 
mutant receptor remained unaffected, while the Gaq coupling was severely reduced 
(Horstmeyer et al., 1996). In contrast, abolishing palmitoylation of the type B 
endothelin receptor [ET B-R] did not affect Gaq coupling, but impaired Gai coupling. 
Thus, palmitoylation appears to play a role in receptor/G-protein coupling. 
Very little is known about the role of the intracellular C-terminal tail in coupling of 
the non-mammalian GnRHRs to their cognate G-proteins. Recently the 51 amino acid 
intracellular C-terminal tail of the cfGnRHR was truncated (Lin et al., 1998). In 
contrast to the wt cfGnRHR that produces IPs in a dose-dependent manner in response 
to Buserelin stimulation, the truncated cfGnRHR mutant did not activate IP 
production. Because no detectable Buserelin binding could be measured for the wt or 
mutant cfGnRHR, it was not clear if the truncation affected receptor expression. No 
direct conclusion can be made from these experiments about the role of the cfGnRHR 
C-terminal tail in G-protein coupling. Furthermore, these authors engineered a 
chimeric rGnRHR/cfGnRHR-C-tail consisting of the intracellular C-terminal tail of 
the cfGnRHR fused to the rGnRHR. This chimeric rGnRHR/cfGnRHR-C-tail had a 
higher Buserelin-induced IP response with a -2 fold decreased EC50 compared to the 
wt rGnRHR. This increased potency was not consistent with the -5 fold increase in 
receptor expression recorded for this chimeric receptor. One can therefore not deduce 
whether the cfGnRHR C-terminal tail plays an important role, if any, in receptor/G-
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protein coupling. However, considering the vast amount of evidence implicating the 
intracellular C-terminal tail of the GPCRs in G-protein coupling, the possibility of a 
similar role in non-mammalian GnRHRs, for example the cGnRHR can not yet be 
excluded. 
• DESENSITIZATION 
The levels of gonadotropin secretion changes dramatically during the course of the 
estrus and menstrual cycle, where LH release peaks prior to ovulation and reaches a 
nadir shortly thereafter. This indicates that gonadotropin release must be under tight 
regulatory control. Furthermore, continuous stimulation of gonadotropes with high 
concentrations of GnRH leads to attenuation of gonadotropin secretion [gonadotrope 
desensitization] in various species, including mammalians (Liu and Jackson, 1984; 
McIntosh and McIntosh, 1985) and non-mammalians (King et al., 1986). Although 
the mechanism(s) involved in gonadotrope desensitization remain to be elucidated, 
this phenomenon proved invaluable in the clinical treatment of pathophysiological 
reproductive disorders, where patients were administered with chronic doses of GnRH 
(Manni et al., 1986; Labrie et al., 1986). 
Desensitization commonly plays a role in GPCR regulation, where agonist-induced 
activation of a GPCR leads to phosphorylation of the activated receptor via G-protein 
coupled receptor kinases [ GRKs] (Inglese et al., 1993; K watra et al., 1993; Ishii et al., 
1994). Subsequently, arrestin binds to the phosphorylated regions of the receptor, 
preventing receptor/G-protein coupling. This uncoupling event is known as 
homologous desensitization and it is responsible for mediating rapid desensitization. 
Unstimulated GPCRs can also undergo desensitization, known as heterologous 
desensitization, but phosphorylation of these receptors is governed by second-
messenger-dependent kinases, ie. protein kinase A and C. Receptor internalization and 
down-regulation are responsible for mediating intermediate- and long-term 
desensitization effects respectively (Bohm et al., 1997). Collectively these processes 
ensure signal termination. 
Most early investigations on rapid homologous desensitization of GPCRs were 
performed on the cAMP-linked P-AR and cGMP-linked rhodopsin receptor. The 
intracellular C-terminal tail of both these receptors was implicated in mediating rapid 
homologous desensitization by phosphorylation of serine/threonine residues in their 
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intracellular C-terminal tail (Savarese and Fraser, 1992). However the a-adrenergic 
receptor undergoes rapid homologous desensitization due to phosphorylation of serine 
residues in its third ICL (Eason et al., 1995). Moffett et al. ( 1996) abolished 
palmitoylation of the ~2-AR C-terminal tail by replacing C
341 with a glycine residue. 
This increased the basal levels of receptor phosphorylation in the C-terminal tail, 
resulting in an uncoupled ~2-AR. Thus palmitoylation of the C-terminal tail might 
play a role in desensitization of some GPCRs. 
Cloning of the mammalian GnRHRs revealed these receptors to be the only GPCRs 
that lack an intracellular C-terminal tail. Therefore a great deal of curiosity was 
ignited as to whether the mammalian GnRHRs can desensitize rapidly. Shortly 
thereafter Davidson et al. (1994) provided evidence suggesting that the mGnRHR 
does not undergo rapid homologous desensitization. Davidson and co-workers 
demonstrated that GnRH-induced IP accumulation increases linearly over lOmin in 
aT3-l cells and in GH3 cells transfected with the mGnRHR. The thyroid releasing 
hormone receptor [TRHR], however displayed desensitization within 5min of 
stimulation in GH3 cells (Davidson et al., 1994). This is in accord with results 
published by Hawes et al. (1992), demonstrating that gonadotrope desensitization in 
response to GnRH is downstream to IP production. 
Furthermore, Anderson et al. (1995) demonstrated that the GnRH-induced Ca2+ 
response attenuated during intermittent GnRH pulses [5min pulses at 15min intervals] 
in both pituitary [aT3-l cells] and non-pituitary HEK293 cells [stably transfected 
with the rGnRHR]. This attenuated Ca2+ response is not a function of Ca2+ pool 
depletion because GnRH-releasable Ca2+ pool refilling occurs in less than lmin 
(McArdle et al., 1996). This suggests that the desensitization might be at the Ca2+ 
mobilization level. In contrast, Willars et al. (1998) showed that aT3-l cells 
pretreated with lOOnM GnRH for 5min were equally robust in mediating a GnRH-
induced Ca2+ response as non-pretreated aT3-l cells. Thus, the comparable GnRH-
induced Ca2+ mobilization from pretreated and non-pretreated aT3-1 cells 
demonstrates that the GnRHR does not desensitize rapidly. 
The aT3-l cell line does not lack the necessary machinery required for rapid 
desensitization, because other Gaq-coupled GPCRs expressed in aT3-l cells undergo 
rapid homologous desensitization of both IP and Ca2+ response (Willars et al., 1998; 
Forrest-Owen et al., 1999). This is hardly surprising because the aT3-1 cell line was 
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previously reported to express GRK.s homologous to the rat GRK.2, GRK.3 and human 
GRK.6 (Neill et al., 1996). Forrest-Owen and co-workers also showed that the lack of 
rapid homologous desensitization of the mGnRHR in aT3-1 cells is not due the 
presence of "spare receptors". This is consistent with results previously published by 
Hawes et al. ( 1992), showing that homologous gonadotrope desensitization is not 
linked to the GnRHR number. To date, no conclusive evidence exists to support rapid 
homologous desensitization in the mammalian GnRHRs as seen in other GPCRs. 
Recently, Hetling et al. (1998) added the intracellular C-terminal tail of the rapidly 
desensitizing rat TRHR [rTRHR] to the rGnRHR, generating the rGnRHR/rTRHR-C-
tail chimera. This chimera was able to desensitize rapidly in response to GnRH in 
both COS-7 [ after 1 Omin] and HEK293 [ within 2min] cells, presumably via the 
rTRHR C-terminal tail. In contrast the wt. rGnRHR did not display rapid homologous 
desensitization. In addition, they also demonstrated that the cfGnRHR that does 
possess an intracellular C-terminal tail was able to undergo rapid homologous 
desensitization in COS-7 cells after about 5min and in HEK293 cells within 100sec. 
Willars et al. (1999) demonstrated that the cfGnRHR undergoes agonist-mediated 
phosphorylation, but not wt rGnRHR. Addition of the cfGnRHR C-terminal tail to the 
rGnRHR, resulted in a chimera [rGnRHR/cfGnRHR-C-tail] that undergoes agonist-
mediated phosphorylation. This suggests that the cfGnRHR is probably 
phosphorylated at its C-terminal tail in response to agonist stimulation. The 
rGnRHR/cfGnRHR-C-tail chimera desensitized rapidly, unlike the wt rGnRHR 
counterpart. It is therefore possible that the cfGnRHR undergoes rapid homologous 
desensitization via its intracellular C-terminal tail, and that the lack of rapid 
desensitization in mammalian GnRHR.s might be due to the absence of an intracellular 
C-terminal tail. 
Both the chicken and catfish GnRHRs internalize rapidly in response to GnRHR 
stimulation (Pawson et al., 1998; Hetling et al., 1998). Pawson et al. (1998) showed 
that truncation of the intracellular C-terminal tail of the cGnRHR reduced the rate of 
agonist-induced cGnRHR internalization from 11.3% per min to 0.55% per min. 
Thus, the C-terminal tail truncated cGnRHR mutant had an agonist-induced 
internalization rate similar to the hGnRHR [0.71% per min], implicating the C-
terminal tail of the cGnRHR in mediating rapid internalization. 
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It therefore appears as though non-mammalian GnRHRs, for example the cGnRHR 
undergo rapid internalization and probably rapid desensitization via their intracellular 
C-terminal tail. These desensitization processes do not occur in mammalian GnRHRs 
and might be because of the evolutionary loss of their C-terminal tail. 
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3. MATERIALS AND METHODS 
3.1 PCR MUTAGENESIS 
Table 3.1: Primers used to truncate the cGnRHR and mutate C
328 to alanine. 
CONSTRUCT PRIMER SEQUENCE 
PRIMER 
cC375STOP* 5' GCACTCGAGCTACACCGTGTTAACGGTTGTCC 3' 
cS366STOP*a 5' GTCACTCGAGTCAGCCACCTGATGTCACCT 3' 
cD356STOP* a 5' GTCACTCGAGTCACCCATCCTTGGTGGTCT 3' 
cT351STOP* a 5'GTCACTCGAGTCACTTCTCTGAGACTGAGATG3' 
cS346STOP* a 5' GTCACTCGAGTCAGATGGGTTTGTGTCTCAC 3' 
cS337STOP* 5'GTCACTCGAGTCAAATGGCTGCTTCAATGCCC3' 
cR330STOP* 5' GACCTCGAGTCAGAGACACAGTTGCACGTCC 3' 
cS320STOP* 5' GTCACTCGAGTCAGGGGGTGTACAGTCCAT 3' 
cC328A* 5'GGACTGTACACCCCAAGCTTTCGGGAGGACGT 
GCAACTGGCTCTCAGGGGCATTGAAGC3' 
• All the primers used for truncation of the cGnRHR C-terminal tail contain an Xho I site underlined 
and a stop codon written in italics. 
• a marked primers were designed by Dr A Fawson who also made their corresponding intracellular 
C-terminally truncated cGnRHR constructs. 
• The cC328A * primer contains a BsrG I restriction site written in blue and a Hind Ill restriction site 
[silent mutation] indicated in green. Included in red is the alanine encoding sequence replacing the 
wt cysteine codon. 
3.1.a Construction of Intracellular C-terminal truncated mutants 
A series of C-terminal tail truncations of the cGnRHR were generated using specific 
antisense primers [listed in table 3.1] containing an Xho I restriction site and a stop 
codon. Each primer was used in combination with pcDNA I/ Amp vector specific T7 
sense primer [5' TAATACGACTCACTATAGGG 3'] and cGnRHR cDNA template 
[cloned into pcDNA I/Amp vector (Invitrogen) between Not I and Xho I] to generate 
PCR fragments encoding cGnRHRs with variable lengths of its intracellular C-
terminus. Each PCR was catalysed by high fidelity Deep Vent polymerase (GIBCO) 
performed under the following conditions: 
1 min at 94 °C [ denaturation of cGnRHR/vector cDN A template] 
lmin at 50°C [annealing of primers to single stranded cDNA] 
17 
lmin at 72°C [elongation of primers into new mutated cDNA strands], where this 
cycle was repeated 25-30 times; followed by 1 Omin at 72°C to complete extension. 
The cGnRHR cDNA in pcDNA I/Amp has only one Ava I restriction site at base pair 
942 of the insert. As depicted in figure 3.A, each PCR product was digested with 
restriction enzymes, Ava I (NEB) and Xho I (NEB), followed by isolation of the PCR 
fragment containing both Ava I and Xho I sticky ends from an 1.5% agarose gel. This 
fragment was purified using the QIAquick spin purification kit (QIAGEN) and ligated 
into pcDNA I/Amp vector construct containing wt cGnRHR cDNA that was 
linearised by Ava I and Xho I. The ligated construct was transformed into DHlOB E. 
coli and grown on ampicillin agar plates. Positive clones were identified by restriction 
digest with Not I (NEB) and Xho I. Mutation of each truncated cGnRHR cDNA was 
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Figure 3.A Schematic representation of the method used to truncate the cGnRHR C-terminal tail by 
employing a PCR-based technique. Primer X [PX] represents any antisense primer given in table 3.1 
used to synthesise truncated forms of the cGnRHR. The vector, pcDNA I/Amp is depicted in black, the 
cGnRHR cDNA in blue, the primers and PCR fragment of the cGnRHR in green. See tex1 for details. 
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3.1.b Construction of point-mutation of c32s to A 
The sense cGnRHR primer cC328A* [table 3.1] contains an alanine encoding 
sequence [GCT] replacing the cysteine 328 encoding sequence [TGT], as well as a 
Hind III [ silent mutation] and BsrG I restriction site. This primer in combination with 
the pcDNA I/Amp vector specific anti sense Sp6 pnmer [5' 
GCATTTAGGTGACACTATA 3'] was used to amplify up the cGnRHR C-terminal 
tail encoding cDNA sequence under the same PCR conditions mentioned in section 
3.la. The cGnRHR cDNA has only one BsrG I restriction site at base pair 1014 of the 
insert. As described in figure 3.B, the A328 encoding PCR product was digested with 
restriction enzymes BsrG I (NEB) and Xho I, followed by isolation and purification. 
The purified fragment containing BsrG I and Xho I sticky ends was ligated into 
pcDNA I/Amp vector construct containing cGnRHR cDNA that was linearised by 
BsrG I and Xho I. DHl OB E. coli cells were transformed with the ligated construct 
and grown on ampicillin agar plates. Ampicillin resistant clones were screened for 
Hind III (NEB) digestion and the positive clones sequenced in order to confirm the 
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Figure 3.B Schematic representation of the strategy used to replace C328 in the cGnRHR with an 
alanine. The sense primer cC328A * has a silent Hind III restriction site and an alanine encoding 
sequence depicted in red. The vector, pcDNA I/Amp is depicted in black, the cGnRHR cDNA in blue, 
the primers and PCR fragment of the cGnRHR in green. See the text for details. 
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3.2 CELL CUL TURING AND TRANSIENT 
TRANSFECTION WITH DEAE-DEXTRAN 
COS-1 cells were maintained in low glucose DMEM media containing 10% heat 
inactivated fetal calf serum [FCS] at 37°C and 10% CO2. For all transient 
transfections COS-1 cells were seeded on 12-well plates coated with poly-D-lysine. 
250000 cells were seeded per well on 12-well plates and cultured overnight in 
lml/well of low glucose DMEM [10% FCS; 0.25% PS (2g/1000ml streptomycin 
sulphate; 2x 106U sodium benzylpenicillin)] at 37°C and 10% CO2. DNA to be 
transfected [2.Sµg/well] and 0.15mg DEAE-Dextran in HEPES-buffered saline 
(137mM NaCl; Sm MKCl; 0.7mM NaH2P04; 2lmM HEPES [pH 7.1]) were added to 
low glucose HEPES-DMEM containing 0.25% PS, making up a volume of 
500µ1/well. The final mixture was added to the cells. Cells were incubated for 4h at 
37°C and thereafter washed once with low glucose HEPES-DMEM containing 0.25% 
PS. lml/well of 200µM chloroquine in low glucose DMEM [2% FCS; 0.25% PS] was 
added to the cells and removed after lh incubation at 37°C, followed by incubation 
with O.Sml/well of low glucose DMEM [10% DMSO; 0.25% PS] for 90sec. 
Thereafter the cells were washed once with low glucose HEPES-DMEM [0.25% PS], 
and fed with lml/well oflow glucose DMEM [10% FCS; 0.25% PS]. 
3.3 WHOLE CELL BINDING ASSAY 
A day after transfection the media of the cells were changed and the cells cultured 
overnight. The following day the cells were washed with lml/well of Buffer I 
(140mM NaCl; 4mM KCl; 20mM acid free HEPES; 8.3mM glucose; l.5ml/l of 0.4% 
phenol red [pH 7.4]) containing 0.1% fatty acid free BSA; lmM MgCh; lmM CaCh. 
The cells were then incubated for 6h at 4°C with 80000cpm/well of [125I]His5-D-
Tyr6( GnRH) made-up in Buffer I containing O. 1 % fatty acid free BSA; 1 mM MgCh; 
1 mM CaCh in a total volume of 600µ1/well. This was done in the presence of 
increasing concentrations [OM; 10·11M; 10·10M; 10"9M; 10·8M; 10"7M] of cold His5 -D-
Tyr6(GnRH) to compete with the radiolabeled [125I]His5-D-Tyr6(GnRH) for receptor 
binding and each concentration was tested in duplicate. In order to determine non-
specific binding, mock-transfected cells were incubated with 600µ1 of the radioactive 
binding solution in the absence of cold His5 -D-Tyr6(GnRH). The radiolabeled media 
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was removed, cells were washed twice with 1 ml/well of Buffer I containing 0.5% 
fatty acid free BSA; lmM MgCh; lmM CaCh and then the cells were solubilised 
with 0.5ml/well of O. lM NaOH. After shaking the plates for 5min, the radioactivity in 
each well was determined in a Gamma counter. 
3.4 INOSITOL-PHOSPHATE ASSAY 
One day after transfection the cells were washed once with Medium 199 containing 
2% FCS; 0.25% PS and then incubated in this medium supplement with l.5µCi/well 
of [3H]myo-inositol. The cells were incubated overnight at 3 7°C, allowing at least 18h 
for label incorporation by the cells before the media was removed. The cells were 
washed twice with lml/well pre-warmed Buffer I [at 37°C] containing 0.1 % fatty acid 
free BSA; lmM MgCh; lmM CaCh with each wash lasting -5min. The washing 
buffer was removed and the cells incubated for lh at 37°C with increasing doses of 
GnRH ligand, OM; 10-10M; 10-9M; 10-8M; 10-7M; 10-6M. The chicken [CI] GnRH was 
made-up in Buffer I containing lmM MgCh; lmM CaCh and lOmM LiCl. The ligand 
solutions were pre-warmed to 37°C and each concentration was tested in duplicate. 
After one-hour stimulation the media was removed and replaced with 1 ml of ice cold 
lOmM formic acid, followed by incubation at 4°C for 30min. Dowex-1 columns [l 
column/sample] were equilibrated with 3ml/column 3M ammonium formate, washed 
with 1 Oml/column distilled water and the samples were loaded onto the columns. The 
samples were washed with lOml/column distilled water, followed by 5ml/column of 
5mM myo-inositol containing 0, IM formic acid. The inositol phosphates were eluted 
from the columns with 3ml/column of IM ammonium formate containing O. lM 
formic acid, into l 4ml/tube of Quicksafe Scintillation liquid (Zinsser Analytical) and 
the radioactivity counted on a beta counter. 
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3.5 CALCULATIONS OF RELATIVE COUPLING 
EFFICIENCY 
The equation used for calculating the relative coupling efficiency values was 
developed by Ballesteros et al. (1998) in which the equation was derived as follows: 
[AR]/Bmax = 1/(1 + Kd/[A]) 
E/Emax = 1/(1 + ECso/[A]) 
Q = E/[AR] 
Substitution of equation 1 and 2 into 3 yields equation 4. 
Q = (1/2) X [(~ + ECso)/ECso] X (Emax1Bmax) 
-Q = Qmutantf Qwild type 
where, 
[AR] = concentration of ligand-receptor complex 
[A] = concentration of unbound ligand 
Emax = maximal receptor activation 





Kd = ICso [this is under conditions where excess radiolabelled ligand is used to 
saturate the receptors expressed on the plasma membrane] 
Bmax = maximal receptor binding 
Q = magnitude of receptor response per agonist-occupied receptor in arbitrary 
Numbers [ efficiency of coupling] 
-Q = coupling efficiency relative to the wild type 
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4.RESULTS 
• THE ROLE OF THE INTRACELLULAR C-TERMINAL 
TAIL IN RECEPTOR EXPRESSION. 
In order to determine whether the intracellular C-terminal tail of the cGnRHR is 
involved in the expression of this receptor, we initially deleted the entire intracellular 
C-terminal tail. A receptor mutant c53205TOP, lacking the C-terminal tail amino 
acids F321 -C375 was constructed in pcDNA I/Amp expression vector and transfected 
into C05-1 cells. No binding or GnRH-induced IP production could be detected for 
this mutant, suggesting that c53205TOP may not be expressed on the plasma 
membrane [ data not showed]. As control, the wt cGnRHR was also tested, resulting in 
cGnRHR expression and a GnRH-induced IP response [figure 4.lA and 4.2A]. The 
maximal Binding [Bmax] and IP [IP max] from the wt cGnRHR was taken as 100%. This 
suggests that the intracellular C-terminal tail of the cGnRHR may be required for 
receptor expression. The intracellular C-terminal tail was then progressively truncated 
to examine whether expression of the cGnRHR is dependent on a specific sequence 
contained in the intracellular C-terminal tail and/or the length of the intracellular C-
terminal tail. As seen in figure 4.lA and table 4.1, cC3755TOP and c53665TOP did 
not have a significantly reduced receptor expression. This indicates that the C-
terminal region of the C-terminal tail from G365 to C375 does not play an important 
role in expression of the cGnRHR. Further truncations significantly reduced receptor 
expression, where progressive shortening of the C-terminal tail resulted in progressive 
reduction ofreceptor expression. A dramatic reduction of 55% expression can be seen 
with truncation of the C-terminal tail at D356 [cD3565TOP] compared to the full-
length cGnRHR. This suggests that the region between G355 and 5366 may be 
important in receptor expression. No further reduction in expression of the cGnRHR 
is seen with truncation of the C-terminal tail at T351 and 5346 . Truncation of the C-
terminal tail at 5337 and R330 resulted in a further decrease in expression to 30% and 
12% respectively. The lowest expression level was displayed by the cR3305TOP 
mutant. This truncated mutant receptor is 10 amino acids longer than the unexpressed 
c53205TOP mutant that lacks the entire C-terminal tail. These results suggest that the 
C-terminal tail of the cGnRHR is important for the expression of this receptor. Figure 
4.18 and table 4.1 shows that the affinities of the intracellular C-terminal truncated 
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cGnRHR mutants are all in the nanomolar range and are relatively comparable to that 
of the wt cGnRHR. This suggests that these truncated mutant receptors retained the wt 
conformation and that the C-terminal tail is not involved in ligand binding. 
Table 4.1 
Homologous competition binding assays were performed on the full-length cGnRHR and its truncated 
counterparts, using cold His5-D-Tyr6(GnRH) to compete against the [125I]His
5-D-Tyr6(GnRH) tracer for 
receptor binding. The maximal binding capacity [Bmax] for each receptor was determined in the absence 
of cold His5-D-Tyr6(GnRH) and is given in percentage. The IC50 values are given in nanomoles [nM]. 
Each experiment was done in duplicate and repeated at least three times. 
CONSTRUCT Bmax (% of wt.) ICso values (nM) 
wt. cGnRHR 100 2.8 ± 1.4 
cC375STOP 92±2 2.5 ± 0.8 
cC366STOP 77 ±35 4.7 ± 1.0 
cD356STOP 45 ±27 5.2 ± 2.5 
cT351STOP 55±28 5.3 ±2.4 
cS346STOP 61 ±28 3.7 ± 1.7 
cS337STOP 30 ± 10 2.4 ± 1.6 
cR330STOP 12± 9 2.0± 1.1 
100 
Figure 4.lA 
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• THE ROLE OF THE INTRACELLULAR C-TERMINAL 
TAIL IN RECEPTOR COUPLING. 
The role of the cGnRHR C-terminal tail in coupling was determined by transfecting 
the truncated cGnRHR constructs into COS- I cells and testing for their ability to 
generate IPs in response to CI GnRH. Figure 4.2A and table 4.2 shows that 
cS337STOP and cR330STOP have a 60% and 24% maximal CI GnRH-induced IP 
production respectively, which is in correlation with their lower level of expression. 
The right-shifted EC5o values of these two truncated mutants is probably also on 
account of their low expression [figure 4.2B and table 4.2]. All the other truncated 
mutants with C-terminal tails longer than that of the cS337STOP mutant had a more 
robust maximal IP production than the full-length cGnRHR [figure 4.2A and table 
4.2]. However, their EC50 values are comparable to that of the full-length cGnRHR 
[figure 4.2B and table 4.2]. The highest maximal IP response was generated by the 
cD356STOP mutant, which had almost a two fold greater IP yield than the wt. Yet, 
the wt cGnRHR had a two fold higher level of receptor expression than the 
cD356STOP mutant. Intuitively this truncated mutant should have a better coupling 
efficiency than the wt cGnRHR. This should also be the case for cS346STOP, 
cT35ISTOP, cS366STOP and possibly cC375STOP as they generate greater IP yields 
than the wt cGnRHR regardless of their lower expression levels. The relative coupling 
efficiency values were therefore determined for all the truncated cGnRHRs using the 
equation given in methods 3.5 (Ballesteros et al., 1998). Indeed, their relative 
coupling efficiency values are bigger than that of the full-length cGnRHR, implying 
that they couple more efficiently to Gaq;11 [ table 4.3 and figure 4.3]. Unexpectedly, 
cS337STOP and cRR330STOP also had relative coupling efficiency values greater 
than the wt cGnRHR, 1.5 and 1.3 respectively. These results indicate that all the C-
terminal truncated receptors couple to Gaq;11 more efficiently than the full-length 
cGnRHR. Thus coupling of the cGnRHR is enhanced in the absence of a full-length 
C-terminal tail, suggesting that the C-terminal tail may play a negative regulatory role 
in Gaq111 coupling. 
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Table 4.2 
A dose response of CI GnRH-induced IP production was determined for the full-length and truncated 
cGnRHRs. The maximal IP production [IPmax] was determined using 1 o-6M CI GnRH and is given in 
percentage. The EC50 values are given in nM. Each experiment was performed in duplicate and 
repeated at least three times. 
CONSTRUCT IP max(% of wt.) 
wt. cGnRHR 100 
cC375STOP 132 ± 16 
cS366STOP 147 ± 33 
cD356STOP 191 ± 53 
cT351STOP 158 ± 27 
cS346STOP 136 ± 27 
cS337STOP 60 ± 12 
cR330STOP 24±6 
Figure 4.2A 
Maximal GnRH-induced IP production [IPmax] 
of the wt and truncated cGnRHRs determined 
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ECso values (nM) 
5.5 ± 4.1 
4.1 ± 3.1 
3.8 ±3.7 
9.1 ± 5.6 
7.4 ± 5.2 
2.9 ± 1.8 
16.6 ± 6.5 
109.9 ± 140.2 
Figure 4.2B 
ECso values of the wt and truncated GnRHRs 
in nM. Determined from CI GnRH-induced IP 
dose-response. 
1801 
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Table 4.3 
Relative coupling efficiency [-Q] of the full-length and C-terminal truncated cGnRHRs, determined as 
explained in 1naterials and methods 3.5, are given in arbitrary numbers. Values larger than one suggests 
better coupling efficiency than the wt cGnRHR. Poorer coupling efficiency than the wt cGnRHR is 
indicated by values smaller than one. 
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• THE ROLE OF CYSTEINE 328 IN EXPRESSION AND 
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Figure 4.4 Alignment of the N-terminal domain of the chicken, catfish, goldfish A and B GnRHR C-
terminal tails. The conserved cysteine residue is depicted in red. 
Alignment of the membrane proximal C-terminal tail sequence of the cGnRHR with 
that of the cfGnRHR, goldfish type A and B GnRHR revealed a conserved cysteine 
residue 8 amino acids downstream to the intracellular TM7 boundary [figure 4.4]. 
Thus we surmised that C328 of the cGnRHR might possibly undergo palmitoylation, a 
modification present on cysteine residues in C-terminal tails of many GPCRs. 
Therefore, C328 of the cGnRHR was mutated to an alanine residue to investigate the 
role of this conserved residue in receptor coupling. Figure 4.5A and table 4.4 shows 
that replacement of C328 with an alanine resulted in a two fold higher receptor 
expression level (204%) than the wt cGnRHR. The affinity of the cC328A mutant was 
1.5 ± 0.3nM, which .is similar to that of the wt cGnRHR, indicating that the cysteine 
to alanine mutation does not affect affinity [figure 4.5B and table 4.4]. A maximal IP 
yield of only 69% was produced by cC328A in response to CI GnRH [figure 4.5C 
and table 4.4], with an EC50 of 7.3 ± 5.5nM, which is similar to that of the wt 
cGnRHR [figure 4.5D and table 4.4]. This markedly reduced IP production from 
cC328A however, is in contrast to the two-fold increase in maximal binding measured 
for this mutant and suggests that coupling of this mutant receptor is decreased. The 
relative coupling efficiency determined for cC328A is 0.3, which is less than that of 
the wt cGnRHR [figure 4.5E and table 4.4]. Thus replacement of C328 with an 
alanine reduces the efficiency with which the cGnRHR couples to Gaq111 , suggesting 
that C328 may play an important role in coupling of the cGnRHR. The cGnRHR has 
another cysteine residue in its C-terminal tail, C375. This is the last residue in the C-
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terminal tail and is not conserved amongst the non-mammalian GnRHRs. This implies 
that C375 might not play a major functional role and is probably not palmitoylated. 
Truncation of this residue [cC375STOP] did not affect expression or binding affinity 
[table 4.1, figure 4.lA and figure 4.18]. The maximal IP production and relative 
coupling efficiency of cC375STOP however increased to 132% and 1.5 respectively 
[table 4.2 and table 4.3]. No change in the ECso was observed compared to the wt 
cGnRHR. 
Table 4.4 
Percentage maximal [125I]His5-D-Tyr6(GnRH) binding [Bm.,J and IC50 [in nM] of the cC328A mutant 
receptor and wt cGnRHR, as determined from homologous competition binding. The percentage 
maximal IP production [IPmaxl and EC50 [in nM] for the wt and cC328A mutant cGnRHR was 
determined from a CI GnRH-induced dose response. Each experiment was performed in duplicate and 
repeated at least three times. Relative coupling efficiency values were calculated as in materials and 
methods 3.5, and are given in arbitrary numbers. 
Relative 
CONSTRUCT Bmax ICso IPmax ECso 
Coupling 
Efficiency (-Q) 
cGnRHR 100 2.8 ± 1.4 100 5.5 ±4.1 1.0 
cC328A 204 ± 21 1.5 ± 0.3 69 ±20 7.3 ± 5.5 0.3 
Figure 4.5 
cC328A was compared to the wt cGnRHR in a homologous competition binding assay and a CI 
GnRH-stimulated dose response reaction. The maximum percentage [1 25I]His5-D-Tyr6(GnRH) binding 
[BmaxL determined in the absence of cold [1 25I]His5-D-Tyr6(GnRH) is shown in figure A. The IC50 is 
given in nM and shown in figure B. The maximum percentage IP production [IPmaxL determined using 
10-6M CI GnRH is shown in figure C. The EC50 values are given in nM and are shown in figure D. 
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In order to gain insight into the role of the C-terminal tail of the cGnRHR on its 
· h 55 · ·d c · 1 -1 d s320 R33o s337 s346 express10n, t e ammo ac1 -termma ta1 was truncate at , , , , 
T351, D356, S366, and C375 [figure 5.1]. These truncated receptors were transiently 
transfected into COS-I cells and tested for their maximal GnRH binding capacity, as 
an indication of their maximum receptor expression level. cS320STOP, the truncated 
cGnRHR that lacks the entire C-terminal tail did not display any binding or GnRH-
induced IP production. This is consistent with results published for the C-terminal 
truncated rhodopsin receptor (Weiss et al., 1994) and type 2 vasopressin receptor 
(Sadeghi et al., 1997). No measurable binding could be detected for the naturally 
occurring C-terminal deficient mutant type 2 vasopressin receptor, V2-R337STOP 
(Sadeghi et al., 1997). Oksche et al. (1998) demonstrated by the use of fluorescence 
microscopy that the V2-R337STOP mutant is produced in similar quantities as the 
full-length V2-R. The V2-R337STOP mutant however, does not reach the plasma 
membrane, but is trapped in the ER. The absence of the C-terminal tail from the V2-
R337STOP may have caused this receptor to be misfolded, resulting in the retention 
of this protein in the ER by a protein folding chaperone (s). Rozell et al. (1998) 
showed that the precursor forms of LHR and FSHR associate with the ER localized 
protein folding chaperone calnexin. These results suggest that some, if not all GPCRs 
interact with protein folding chaperones. Protein folding chaperones are believed to 
facilitate the proper folding of proteins and retain misfolded proteins in the ER 
(Rudden and Bedows, 1997). cR320STOP may also have been folded aberrantly and 
retained in the ER, resulting in the absence of GnRH receptor binding on the cell 
surface. Thus the C-terminal tail of the cGnRHR may play a role in stabilizing the 
proper receptor conformation and promoting receptor expression. Addition of the 
cfGnRHR intracellular C-terminal to the rGnRHR resulted in a 5-fold increase in 
receptor expression compared to the wt rGnRHR, which was reversible with 
truncation of the C-terminal tail from this chimeric GnRHR (Lin et al., 1998). This 
suggests that the intracellular C-terminal tail of both of these non-mammalian 
GnRHRs [chicken and catfish] may possess certain elements that play an important 
role in receptor expression. It is reasonable to assume that these elements might be 




















































































































































































































































































































































































































































































































































































































































In this study the cR330STOP mutant, which has a 9 amino acid C-terminal tail was 
the shortest truncated cGnRHR engineered that could be detected on the cell surface 
by binding studies. This suggests that the N-terminal region of the C-terminal tail, 
between P319 and G331 may be important in the proper folding and/ or expression of 
the cGnRHR. Interestingly, the N-terminal domain of the C-terminal tail in the 
cGnRHR has a high homology with that of other non-mammalian GnRHRs, including 








Gfb . GnRHR 
Gfa.GnRHR 
Consensus 
R GIEAA, QHVRHKPISVSE:EcrTKDGDVNG VfNO S PHFSGHRREVSGEAESDL RRNQN LKSLDRLSVRRGGASREAESDL ORTP PRSLDRIPHENTSPTRB •••. 












Figure 5.2 Alignment of primary sequences of the non-mammalian GnRHR C-terminal tails, including 
the chicken, catfish, and goldfish type A and B GnRHRs. All the residues in blue are identical, residues 
in pink have 75% conservation and the residues written in turquoise are 50% conserved. 
The shortest length of intracellular C-terminal tail required for proper folding and 
expression is not known from our results, because no truncations were made between 
S320 and R330. Nevertheless, these results suggest that the membrane proximal domain 
of the cGnRHR C-terminal tail may be required for proper receptor folding and 
expression. This is consistent with results published for the rat type la angiotensin 
receptor [AT1a-R] (Gaborik et al. , 1998), bovine Rh-R (Weiss et al. , 1994) and type 2 
vasopressin receptor (Sadeghi et al. , 1997; Oksche et al., 1998). Gaborik et al. (1998) 
showed that replacement of F309 [located in the membrane proximal region of the 
AT1a-R] with an alanine reduced the cell surface expression by 80%. This specific 
phenylalanine residue is highly conserved in most GPCRs, including the non-
mammalian GnRHRs [chicken, catfish, goldfish type A and B GnRHR] as seen in 
figure 5.3 . Therefore, it may be possible that F321 plays a similar role in expression of 
the cGnRHR, and that this function is conserved in all the non-mammalian GnRHRs. 
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AT1a-R KK F K K
311 
RhR K Q F R N315 
cGnRHR p s F R E323 
cfGnRHR p s F R A334 
GfaGnRHR p s F R A323 
GfbGnRHR p s F R A336 
Figure 5.3 Alignment of the membrane proximal domain of the C-terminal tail of the type lA 
angiotensin receptor and bovine rhodopsin receptor with non-mammalian GnRHRs. A 
conserved phenyalanine [F] is depicted in red and the conservation of a positive charge in 
blue. 
In addition, alanine replacement of the four lysine residues clustered around F
309 
[K307, K308, K310 and K311] completely abolished expression of the AT1a-R. A mutant 
containing alanines replacing both K310 and K311 had a 5 fold reduced receptor 
expression compared to the wt AT13-R (Gaborik et al., 1998). Similarly, substitution 
of all the positively charged residues in the intracellular C-terminal tail of the VrR 
[R337, R344, R346 and K367] with negatively charged glutamine residues, markedly 
reduced the cell surface receptor expression to 30% of the wt expression (Oksche et 
al., 1998). These results suggest that positive charges contained in the intracellular C-
terminal tails of GPCRs may be critical for receptor expression. Non-mammalian 
GnRHRs possess a highly conserved arginine residue [figure 5.3] at a position 
homologous to K310 of the AT 13-R. This conserved arginine may therefore have a 
conserved role in promoting receptor expression of non-mammalian GnRHRs. The 
presence of F321 and R322 in the C-terminal tail of the cR330STOP-truncated mutant 
may therefore be responsible or contribute to the expression of this truncated receptor 
on the cell membrane. Our results show that the cR330STOP mutant has only 12% 
cell surface receptor expression relative to the wt receptor, indicating the involvement 
of additional elements in promoting receptor expression. Progressive increase in the 
length of the C-terminal tail of the cGnRHR progressively increased the cell surface 
receptor expression [figure 4.lA and table 4.1]. This suggests that these elements 
reside in the intracellular C-terminal tail downstream to L329 [figure 5.1]. The 
cGnRHR possesses five additional positively charged residues in its intracellular C-
terminal tail, R330, R341, K343, K350 and K353 as seen in figure 5.1 that may also be 
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involved in promoting receptor expression on the cell surface (Gaborik et al., 1998; 
Oksche et al., 1998). 
An increase in the length of the cGnRHR C-terminal tail from L329 to 1336 
[cS337STOP] resulted in more than two fold increase in receptor expression 
compared to cR330STOP [figure 4.lA and table 4.1]. R330 resides within this 
extended C-terminal tail region and is conserved between the chicken and type A 
goldfish GnRHR [figure 5.2]. This is the only positively charged residue present in 
the sequence that extends the C-terminal tail from cR330STOP to cS337STOP 
truncation and may therefore contribute to the increase in expression of cS337STOP. 
Another highly conserved residue that resides between L329 and I336 of the cGnRHR is 
C328 [figure 5.2]. This residue does not appear to be involved in promoting cGnRHR 
expression, because substitution of C328 with an alanine did not impair receptor 
expression, but yielded a two fold higher expression than the wt cGnRHR [figure 
4.5A and table 4.4]. C328 can therefore not be responsible for the -18% higher 
receptor expression of cS337STOP compared to cR330STOP. Further extension of 
the C-terminal tail from I336 to I345 [ cS346STOP] resulted in two fold higher 
expression of cS346STOP compared to cS337STOP [figure 4.lA and table 4.1]. Two 
positively charged residues [R341 and K343] are present in this 9 amino acid extension, 
of which the positive charge of K343 is conserved amongst the non-mammalian 
GnRHRs as seen in figure 5.2. 
No further increase in receptor expression was observed with extension of the 
cGnRHR C-terminal tail from I345 to K350 [ cT3 51 STOP] or K350 to G355 
[cD356STOP]. It is noteworthy though that each of these two receptor extensions 
possesses a positively charged residue, K350 and K353 respectively of which neither is 
conserved. A further increase in expression was obtained with extension of the C-
terminal tail from G355 to G365, and wt levels of expression reached with increase in 
length of the C-terminal tail from G365 to V374 [figure 4.lA and table 4.1]. The 
b G3ss d C31s d . . . l h d .d sequence etween an oes not contam any pos1t1ve y c arge rest ues, yet 
the presence of this sequence improved receptor expression to wt levels [figure 4.lA 
and table 4.1]. These results indicate that other sequences or elements present in the 
C-terminal tail beyond G355, in addition to positively charged residues might play a 
role in promoting receptor expression of the cGnRHR. Truncation of C375, the last 
amino acid from the cGnRHR C-terminal tail, did not alter the cell surface expression, 
indicating that C375 does not play a role in receptor expression. All the truncated 
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cGnRHRs, as well as the cC328A mutant had affinities in the range of 2nM to 7nM, 
which is similar to that of the wt. This indicated that truncation of the cGnRHR C-
terminal tail from R 330 and point mutation of C
328 to alanine did not alter the tertiary 
structure of the cGnRHR. No universal consensus sequence for promoting GPCR 
expression is known. Therefore it is difficult to suggest which residues in the distal 
part of the cGnRHR C-terminal tail are responsible for increasing receptor expression 
to wt levels. The contrasting finding that mammalian GnRHRs, which don't have a C-
terminal tail, are expressed while the cGnRHR is not expressed without a C-terminal 
tail, suggests that mammalian GnRHR expression is dependent on different domains 
within the receptor. 
Newly synthesized proteins are mainly sorted and packaged for their different 
destinations in the trans-Golgi network [TGN]. It has been shown that proteins are 
tagged with information in their primary sequence that dictates their final destinations. 
Proteins destined to reside in the ER are tagged with a KDEL motif (Pelham, 1990; 
Vaux et al., 1990), whereas proteins destined for delivery to lysosomes are tagged 
with a mannose-6-phosphate unit (von Figura and Hasilik, 1986). The use of a 
monoclonal antibody against the Rh-RC-terminal tail facilitated in implicating the C-
terminal tail in sorting and trafficking of newly synthesized Rh-R to the rod outer 
segment membrane (Deretic et al., 1996). This antibody recognizes the last 9 amino 
acids on the C-terminal of the Rh-R. Formation of post-Golgi vesicles containing 
newly synthesized Rh-R were severely inhibited by this antibody m a cell-free 
[ membrane extract] assay. Deretic et al. ( 1998) demonstrated that peptides 
corresponding to the last 24 amino acids of the frog and bovine Rh-RC-terminal tail 
have a similar inhibitory effect. These peptides significantly impaired post-Golgi 
trafficking and trapped newly synthesized Rh-Rs in the TNG. Post-Golgi trafficking 
was repaired with truncation of the last 5 amino acids [QVS(A)PA] from these 
peptides. These residues are highly conserved at the end of the C-terminal tail of the 
Rh-R family and may therefore be required for post-Golgi vesicle formation and Rh-R 
trafficking. This sequence motif is suggested to serve as a sorting sequence 
recognized in the trans-Golgi by factors involved in transport of the Rh-R out of the 
trans-Golgi to post-Golgi vesicles (Deretic D., 1998; Deretic et al., 1998). This 
sorting signal is not conserved amongst GPCRs outside the Rh-R family. 
Nevertheless, it may be possible that the C-terminal tail of most GPCRs are tagged 
with a sorting signal, considering the evidence implicating the C-terminal tail in 
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GPCR expression. Though very little is known about the trafficking of newly 
synthesized GPCRs, it is apparent that more than one sequence motif in the 
intracellular C-terminal tail governs GPCR expression. This may very well be true for 
the cGnRHR and other non-mammalian GnRHRs (Lin et al, 1998). 
All the truncated cGnRHRs were tested for their ability to generate second messenger 
IP3 in response to CI GnRH. This was done in order to determine whether these 
truncated receptors are functional. All the truncated mutants were active, except 
cS320STOP, which was therefore not further investigated [figure 4.2A]. Progressive 
truncation of the cGnRHR C-terminal tail from the last residue, C
375 to S346 resulted in 
truncated receptors that generate greater levels of IPs than the full-length cGnRHR. 
Interestingly, all these truncated receptors had a lower cell surface expression than the 
wt cGnRHR. The highest maximal GnRH-induced IP production was generated by 
cD356STOP. This truncated cGnRHR produced an almost two-fold greater IP yield 
[-191 % ] than the wt, yet its cell surface expression is approximately half [-45%] that 
of the wt. It therefore appears as though truncation of the cGnRHR C-terminal tail 
between I345 and C375 improved coupling efficiency. Ballesteros et al. (1998) derived 
a formula to determine coupling efficiency [ described in methods 3.5] and used it to 
compare coupling efficiency between point mutated hGnRHRs and their wt 
counterpart. By applying this formula, we indeed established that all the truncated 
receptors between I345 and C375 have greater coupling efficiency values than the full-
length cGnRHR. In addition, we found that cS337STOP and cR330STOP also have 
coupling efficiency values greater than the wt cGnRHR. These results suggest that the 
cGnRHR couples more efficiently to its cognate G-protein in the absence of its 
intracellular C-terminal tail. Similar results were obtained for the type 2 histamine 
receptor [H2-R] where partial truncation of its C-terminal tail enhanced second 
messenger cAMP production (Fukushima et al., 1997). Interestingly, it was found that 
progressive shortening of the P-type prostaglandin E receptor [EP3P-R] C-terminal 
tail resulted in partial to complete constitutive activation of the resultant mutant 
receptors (Hizaki et al., 1997). Hizaki et al. ( 1997) proposed that the C-terminal tail 
of the EP3P-R plays a role in constraining this receptor into its inactive conformation. 
The level of constitutive activation was inverse I y related to the length of the EP3 P-R 
C-terminal tail. No constitutive activation was detected for any of our truncated 
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cGnRHRs. Nevertheless, it might be possible that the C-terminal tail of the cGnRHR 
also plays an inhibitory role in receptor/G-protein coupling by masking intracellular 
domains that couple to Gaq111 . Truncation of the C-terminal tail of the cGnRHR 
would thus more readily expose such domains to Gaq111 and improve coupling 
efficiency. This would imply that the C-terminal tail of the cGnRHR distal to R
330 
might not be directly involved in promoting receptor/G-protein coupling. No 
truncations were made between S
320 and R330 of the cGnRHR C-terminal tail. 
However, replacement of the highly conserved C
328 with alanine impaired receptor/G-
protein coupling, suggesting that this C
328 might be involved in coupling of the 
cGnRHR to Gaq111 . The membrane proximal domain of the C-terminal tail generally 
contains determinants that contribute to G-protein coupling (O'Dowd et al., 1988; 
Cotecchia et al., 1990). Thus, the N-terminal domain of the cGnRHR C-terminal tail, 
between S320 and R330 can therefore not be ruled out as a possible G-protein-coupling 
domain. 
Intuitively, one would expect that a mutant receptor [for example cD356STOP] that 
has a significantly lower expression, but greater coupling efficiency than its wt, would 
have a left-shifted EC50 [improved potency]. Instead, none of our truncated cGnRHRs 
had improved potencies. All the truncated cGnRHRs have ECso values similar to that 
of the full-length cGnRHR, indicating that truncation of the C-terminal tail beyond 
L329 did not alter the receptor potency [figure 4.28 and table 4.2]. This suggests that 
the enhanced levels of IPs generated by the truncated receptors might not be due to 
improved coupling efficiency per se, if at all. It might be possible that the coupling 
efficiencies of the truncated cGnRHRs did not improve at all, but that alternate factors 
are responsible for their robust IP production. Such factors would include the 
difference in the rate of internalization and desensitization between the truncated 
receptors and the wt. This is not taken into consideration in the coupling efficiency 
equation derived by Ballesteros et al. ( 1998). 
Pawson et al (1998) demonstrated that the cGnRHR undergoes rapid internalization at 
a rate of 11.3% per minute. Truncation of the C-terminal tail at S
337 [cS337STOP] 
severely reduced the GnRH-induced receptor internalization to 0.55% per minute. 
These results implicated the C-terminal tail of the cGnRHR in mediating rapid 
internalization. Similarly, the C-terminal tail of the H2-R has been shown to be 
important for mediating rapid internalization (Fukushima et al., 1997). Truncation of 
38 
the last 51 amino acids from the H2-R C-terminal tail abolished rapid internalization 
without affecting desensitization. In addition, the resultant mutant, T
308 yielded a 
cAMP production that was 1.5 times higher than that of the full-length H2-R. The 
absence of internalization of the T
308 mutant allowed this receptor to be retained on 
the cell surface much longer than its wt counterpart. This might permit a longer time-
period for receptor/G-protein interaction. The cAMP production of the T
308 mutant 
would therefore be more robust than the wt H2-R. This might also explain the 
enhanced IP production of the truncated cGnRHRs. The truncated cGnRHRs might 
have a higher retention time on the cell membrane, allowing a longer period of 
receptor /G-protein coupling. Thus resulting in an enhanced level of IP production 
from the truncated cGnRHRs compared to the full-length cGnRHR. 
The specific determinants in the cGnRHR C-terminal tail responsible for mediating 
rapid internalization are yet to be identified. Nevertheless, the C-terminal tail of the 
cGnRHR is rich in serine/threonine residues, possessing 6 serines and 6 threonines 
[figure 5.1]. Serine/threonine residues have been shown to play a role in promoting 
rapid internalization of various GPCRs (Benya et al., 1993; Fukushima et al., 1997; 
Bohm, 1997). After agonist stimulation, serine/threonine residues in the C-terminal 
tail of the activated GPCR are phosphorylated by G-protein-coupled receptor kinases 
[GRK.s]. GRK.s are cytosolic protein kinases that are recruited to activated GPCRs in 
the plasma membrane. Arrestin molecules bind to the phosphorylated serine/threonine 
regions and are believed to serve as adapter molecules that allow interaction between 
the internalization machinery and the GPCR (Ferguson et al., 1996). Progressive 
shortening of the cGnRHR resulted in the loss of serine/threonine residues with each 
truncation, except for cC375STOP. The cR330STOP and cS337STOP did not display 
enhanced levels of IP production [figure 4.2A and table 4.2], but greater coupling 
efficiency values than the full-length cGnRHR [figure 4.3 and table 4.3]. However, 
expression of cR330STOP and cS337STOP was reduced eight and three fold 
respectively [figure 4.lA and table 4.1]. Their maximal IP production might 
therefore be more robust than that of the wt cGnRHR, if their cell surface expression 
was equivalent to the wt. 
Phosphorylation of serine/threonine residues in the C-terminal tail of many GPCRs by 
GRK.s is also associated with rapid desensitization. Arrestin molecules bind to these 
phosphorylated areas, prevent receptor/G-protein coupling and desensitizes the 
39 
activated receptor (Bohm, 1997). The cfGnRHR has been demonstrated to internalize 
and desensitize rapidly in HEK-293 cells, which is most probably mediated via its 
intracellular C-terminal tail that possesses nine serines (Heding et al., 1998). Addition 
of the cfGnRHR C-terminal tail to the rGnRHR induced the chimeric receptor to 
undergo phosphorylation and desensitize rapidly in response to GnRH (Willars et al., 
1999). It is not yet known whether the cGnRHR undergoes rapid desensitization. 
Considering that the cfGnRHR desensitizes rapidly and that the cGnRHR C-terminal 
tail is also rich in serine/threonine residues, it might be possible for the cGnRHR to 
desensitize rapidly. Rapid internalization and desensitization has been shown to occur 
independently via different molecular determinants in the C-terminal tail of GPCRs, 
including AT1a-R (Thomas et al., 1995) and H2-R (Fukushima et al., 1997). Of the 
thirteen serine/threonine residues present in the H2-R, only T
315 was found to be 
involved in rapid internalization, but not rapid desensitization of the H2-R. It might 
therefore be possible that several of the serine/threonine residues present in the 
cGnRHR C-terminal tail are involved in rapid internalization of this receptor, while 
other serine/threonine residues present in the C-terminal tail might be required for 
rapid desensitization. Progressive truncation of the cGnRHR C-terminal tail might 
have reduced or abolished rapid desensitization. This would prevent or slow down the 
attenuation of signaling, explaining the enhanced maximal IP production by the 
truncated cGnRHRs. Truncation of the NK2-R abolished rapid desensitization and 
resulted in an enhanced IP production (Alb las et al., 1995). Thus, the absence of rapid 
internalization and desensitization might cooperatively or independently have been 
responsible for the robust IP production from the truncated cGnRHRs. 
Most GPCRs have one or more cysteine residues in the membrane proximal domain 
of their C-terminal tail that is palmitoylated, including the V2-R (Schulein et al., 1996) 
and a2A-R (Kennedy and Limbird, 1993). This post-translational modification has 
been implicated in regulatory processes, including G-protein coupling, internalization 
and desensitization of various GPCRs (Bohm et al, 1997). C328 of the cGnRHR is 
highly conserved amongst the non-mammalian GnRHRs, including the type A and B 
goldfish GnRHR and the cfGnRHR [figure 5.2]. Our results show that mutation of 
C328 to alanine [ cC328A] increased the expression two fold, while reducing the 
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maximal IP production and coupling efficiency to -69% [figure 4.SC and table 4.4] 
and 0.3 [figure 4.SE and table 4.4] respectively. 
This reduced IP production and coupling efficiency value suggest that the cGnRHR-
Gaq111 coupling was severely impaired. Horstmeyer et al. (1996) replaced a cluster of 
five cysteine residues in the C-terminal tail of the type A endothelin receptor [ETA-R], 
proximal to the membrane with alanines and serines respectively. This abolished 
palmitoylation and IP production without affecting the cAMP production. These 
cysteines are conserved in the type B endothelin receptor [ET s-R] and substitution of 
three of them by serines abolished palmitoylation and coupling of this receptor with 
both Gai and Gaq (Okamoto et al., 1997). These results suggest that palmitoylation in 
some GPCRs might play a role in G-protein coupling. The severe reduction in IP 
production from cC328A indicates that this residue might be involved in receptor/G-
protein coupling. Furthermore, substitution of C
341 with glycine in the P2-AR C-
terminal tail abolished palmitoylation, severely impaired cAMP production and 
increased basal levels of receptor phosphorylation in the C-terminal tail (Moffett et 
al., 1996). Substitution of S345 and S346 by alanines in the C34 l G P2-AR mutant 
reduced basal phosphorylation and restored receptor-Gas coupling to that of the wt 
P2-AR. The increased basal levels of phosphorylation uncoupled the C341G mutant 
from Gas resulting in reduced cAMP production. Moffett et al. (1996) suggested that 
palmitoylation of the wt P2-AR constrains its C-terminal tail into a conformation that 
reduces the accessibility of S
345 and S346 to protein kinase A [PKA]. This prevents 
phosphorylation at these two serines, allowing the receptor to couple normally to Gaq. 
This might also be applicable to the cGnRHR, provided that this receptor undergoes 
desensitization. The replacement of C
328 with alanine may also increase basal 
phosphorylation levels of this mutant cGnRHR, promoting the onset of receptor 
phosphorylation and uncoupling prior to receptor activation. No direct evidence exists 
to prove that C328 of the cGnRHR is palmitoylated. However, the conservation of this 
residue amongst non-mammalian GnRHRs and the impairment in receptor/G-protein 
coupling from cC328A, suggests that the cGnRHR might be palmitoylated at C
328
. 
Palmitoylation of this residue might serve a structural purpose that facilitates coupling 
or plays a role in receptor phosphorylation. 
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In conclusion, complete truncation of the cGnRHR C-terminal tail abolished agonist 
binding and GnRH-induced IP response, whereas progressive truncation reduced 
receptor expression. This suggests that the C-terminal tail of the cGnRHR might be 
required for cell surface expression of the cGnRHR by playing a role in trafficking. 
Mutation of C328 to alanine and shortening of the cGnRHR C-terminal tail might not 
have altered the tertiary structure of the resultant mutant receptors since receptor 
affinity did not change. In addition, the membrane proximal region of the C-terminal 
tail may play a role in the proper folding of the newly synthesized receptor. The 
enhanced IP and coupling efficiency values indicate that shortening of the C-terminal 
tail might improve coupling. However the similarity in EC50 values between the 
truncated and full-length cGnRHR suggest that alternate processes might be 
responsible for the enhanced IP response. These include a possible loss or reduction in 
the rate of internalization and/or desensitization with truncation of the C-terminal tail. 
Substitution of the highly conserved C
328 with alanine severely impaired coupling, 
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